Evaluating an e-device to monitor the type 2 high unified airway response to dupilumab

Patients with unified airways disease (UAD) who have asthma and concomitant chronic rhinosinusitis with nasal polyps (CRSwNP) are often difficult to manage and have a higher burden of type 2 (T2) inflammation as compared to those with asthma or nasal polyps (NP) alone.1 Few studies have prospectively looked in detail at concomitant upper and lower airway outcomes in patients with T2 high UAD in response to biologics.2 Evaluating the clinical burden of upper and lower airway disease in response to treatment can be challenging using conventional analogue paper diary recordings of peak nasal inspiratory flow (PNIF) and peak expiratory flow (PEF) along with symptoms scores.
Source: Annals of Allergy, Asthma and Immunology - Category: Allergy & Immunology Authors: Tags: Letters Source Type: research